UPDATE: Biogen (BIIB) Initiated at Neutral at UBS
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $218.03 +1.72%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
(Updated - October 27, 2020 4:58 PM EDT)
UBS analyst Colin Bristow starts Biogen (NASDAQ: BIIB) at Neutral, PT $268.00.
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
Create E-mail Alert Related Categories
New Coverage, Trader TalkRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
